WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
On 17 November 2022, the CJEU delivered essentially two decisions on the parallel trade of medicines. The first concerned the rebranding of generic medicines to the branded reference medicine (in joined cases C-253/20 and C-254/20), and about which we published a blog on 24 November 2022. The second addressed the impact of anti-tampering devices on the possibility, and objective necessity, to rebox (in C-224/20 and C-147/20), and about which we published a blog on 2 December 2022.
Contact
Recommended articles
CJEU C-793/22 Biohemp – Indoor Cannabis Cultivation: The CJEU Weighs in
The Cannabis sativa L. plant serves a wide range of purposes, many of which are uncontroversial. It can be grown in the EU, in which context it is commonly called ‘hemp’. The plant notably produces cannabidiol (CBD), which the Court of Justice of the European Union has unequivocally ruled is not a narcotic drug. Nonetheless, some EU Member States remain reluctant to accept hemp cultivation.
Read on
Deepfakes in the music industry: Will the AI Act change the tune?
The emergence of deepfake technology, particularly within the music industry, has sparked significant debate and concern. Deepfakes, which are synthetic media generated using AI to replicate and/or manipulate a known artist’s likeness and/or voice, have the potential to revolutionise the music industry.
Read on
Belgium gears up to enforce the EU Deforestation Regulation
The EU Deforestation Regulation (EUDR) was published on 9 June 2023 and came into force on 29 June 2023. Member States, including Belgium, must establish legal frameworks for enforcement.
Read on